All In Biotech

Drug Trial Radar · NCT07092865

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

A Phase 2b, Non-randomized, Controlled, Open-label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvanted RSVPreF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 Years of Age)

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

168

Actual

Start

Aug 6, 2025

Primary completion

Jan 12, 2027

Study completion Jul 16, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • Adjuvanted RSVPreF3 vaccineBiological

    1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV-A neutralizing titers expressed as Geometric mean titers (GMTs)Time frame: At Visit 1 (Day 1) of the current study
  2. RSV-B neutralizing titers expressed as GMTsTime frame: At Visit 1 (Day 1) of the current study
  3. RSV-A neutralizing titers expressed as Mean geometric increase (MGI)Time frame: At Visit 1 (Day 1) of the current study over 30 days post last dose in the RSV OA=ADJ-023 study
  4. RSV-B neutralizing titers expressed as MGITime frame: At Visit 1 (Day 1) of the current study over 30 days post last dose in the RSV OA=ADJ-023 study
  5. RSV-A neutralizing titers expressed as GMTsTime frame: At Visit 2 (Day 31) of the current study
  6. RSV-B neutralizing titers expressed as GMTsTime frame: At Visit 2 (Day 31) of the current study
  7. RSV-A neutralizing titers expressed as GMTsTime frame: At Visit 3 (Day 180) of the current study
  8. RSV-B neutralizing titers expressed as GMTsTime frame: At Visit 3 (Day 180) of the current study

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Temple, Texas

  • GSK Investigational Site

    Camperdown, New South Wales, Australia

  • GSK Investigational Site

    Birtinya, Queensland, Australia

  • GSK Investigational Site

    Herston, Queensland, Australia

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Giessen, Germany

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Palermo, Italy

  • GSK Investigational Site

    Pavia, Italy

  • GSK Investigational Site

    Siena, Italy

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Hyōgo, Japan

  • GSK Investigational Site

    Kumamoto, Japan

  • GSK Investigational Site

    Okayama, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    A Coruña, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Córdoba, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Santander, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.